Inventiva receives positive opinion on orphan drug designation in the European Union for IVA337 - a treatment for Systemic Sclerosis (SSc)
04-Nov-2014 -
Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as ...
drug discovery
Orphan Drug Designation
systemic sclerosis